Would a CYP2B6 test help HIV patients being treated with efavirenz?

Author： Sukasem Chonlaphat   Sungkanuparph Somnuek  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.9, 2013-07, pp. : 999-1001

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

By Desta Zeruesenay   Saussele Tanja   Ward Bryan   Blievernicht Julia   Li Lang   Klein Kathrin   Flockhart David A   Zanger Ulrich M  

Pharmacogenomics, Vol. 8, Iss. 6, 2007-06 ,pp. : 547-558

Future Medicine

Access to resources Recommend Favorite

CYP2B6 516TT carriers benefit from efavirenz dose reduction

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir

By Millán Olga  

Clinical Pharmacokinetics, Vol. 44, Iss. 5, 2005-01 ,pp. : 525-538

Adis International

Access to resources Recommend Favorite

Molecular Characterization of CYP2B6 Substrates

By  

Current Drug Metabolism, Vol. 9, Iss. 5, 2008-06 ,pp. : 363-373

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients

By Sriwiriyajan Somchai   Mahatthanatrakul Werawath   Ridtitid Wibool   Jaruratanasirikul Sutep  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 5, 2007-05 ,pp. : 479-483

Springer Publishing Company

Access to resources Recommend Favorite